| Aug 14 |
Biora Therapeutics Second Quarter 2024 Earnings: EPS: US$0.18 (vs US$1.47 loss in 2Q 2023)
|
| Aug 13 |
Q2 2024 Biora Therapeutics Inc Earnings Call
|
| Aug 12 |
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
|
| Aug 12 |
Biora Therapeutics GAAP EPS of -$0.04 beats by $0.41, revenue of $0.32M
|
| Aug 12 |
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
| Aug 12 |
Biora Therapeutics Announces Funding Agreement with Existing Investors
|
| Aug 8 |
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
|
| Aug 6 |
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
|
| Jul 18 |
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
|
| Jul 8 |
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
|
